What's New

News

Nippon Kayaku's news releases are issued to inform our stakeholders of the latest information regarding the Company.
While some news releases may contain information about pharmaceutical products (including those under development), they are intended solely for disclosure purposes to members of the media, shareholders, and investors, and are not intended for advertising or promotional purposes, nor to provide medical advice.

2022/11/16
Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody PDF
PageTop
Our Business
R&D
Corporate Information
Global Netowork
Investor Relations
Integrated report
Sustainability